$RNTX News

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

Rein Therapeutics To Present Data On Inhaled LTI-03 For Idiopathic Pulmonary Fibrosis At European Respiratory Society 2026 Congress

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

FDA Grants Rein Therapeutics Fast Track Designation For LTI-03

HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW Trial

Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4

Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Rein Therapeutics Q1 EPS $(0.19) Beats $(0.49) Estimate

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics shares are trading lower. The company issued an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis.

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis